The discovery of a PD-1-independent mechanism of anti-PD-L1 mAb antitumor efficacy via the activation of PD-L1+ NK cells provides a potential explanation to why some patients lacking PD-L1 expression on tumor cells still respond to anti-PD-L1 mAb therapy. The gene discussed is PDCD1; the disease is neoplasm.